FULC Research and Charts

FULC - Fulcrum Therapeutics Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-16 (Delayed quote data 2025-01-06)

Last 4.92	Change ⇓ -0.16 (-3.15%)	Volume 471,290
	Open 5.11	High 5.17	Low 4.87

8EMA (Daily) 4.79	40EMA (Daily) 4.24	50EMA (Daily) 4.25	STO (Daily) 79.247	MACD Hist (Daily) 0.093
8EMA (Weekly) 4.460	40EMA (Weekly) 5.46	50EMA (Weekly) 5.67	STO (Weekly) 74.449	MACD Hist (Weekly) 0.489


Company Profile
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. It has developed a proprietary product engine that employs to identify and validate cellular drug targets that can modulate gene expression. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle-wasting disorder that leads to physical impairments and disability.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.